Navigation Links
Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS)

ly oral laquinimod, are very exciting for the MS community--both patients and researchers," said Shlomo Yanai, President and CEO of Teva Pharmaceutical Industries Ltd. "Teva will soon initiate Phase III studies to confirm oral laquinimod's therapeutic benefits, and we expect to begin enrollment of the trial later this year."

About the Study

Study participants were required to have experienced one or more relapses in the year prior to entry and at least one Gd-enhancing lesion at screening. The patients (n=306) in the study were randomized to receive placebo (n=102), 0.3 mg dose of laquinimod (n=98) or 0.6 mg dose of laquinimod (n=106). At entry, active treatment and placebo groups were comparable for demographic, clinical and MRI characteristics.

Patients were assessed clinically and by MRI scan at week -4, baseline, and monthly from weeks 12 to 36. The primary outcome of the study was the cumulative number of Gd-enhancing lesions at weeks 24, 28, 32 and 36. Secondary outcomes of the study included additional MRI metrics and confirmed relapse rate.

The laquinimod 0.6 mg dose showed a reduction compared with placebo in the cumulative number of enhancing lesions per scan in the last four scans (mean SD= 2.6 5.3 vs. 4.2 9.2, p = 0.0048); treatment with the 0.3 mg dose showed no significant difference. Significant differences in favor of the 0.6 mg dose were found for most examined secondary and exploratory MRI-based outcome measures. Trends favored the group receiving the 0.6 mg dose on measures of annual relapse rate (0.52 +/- 0.92 vs. placebo 0.77 +/- 1.25; p = 0.21), relapse-free subjects (70.8 percent vs. 62.7 percent; p = 0.33) and time to first relapse (p = 0.14).

Treatment with both 0.3 and 0.6 mg doses of laquinimod were well tolerated with only some transient and dose-dependent increases in liver enzymes.

About laquinimod

Laquinimod is a novel once-daily, orally administered immunomodulatory compound developed a
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:10/17/2014)... Germany , October 17, 2014 ... big pharma companies. The challenge with this is ... their information with their competition. Putting this together ... announce we,ve cracked it! We,ve asked big pharma companies to ... of their cold chain strategies - with one caveat - ...
(Date:10/16/2014)... Oct. 16, 2014 Boston Scientific Corporation (NYSE: ... for the ACCOLADE TM pacemaker family. When implanted ... are the first to enable patients to receive full-body ... systems. In addition, the Boston Scientific ImageReady TM ... energy scan sequences, and featuring a programmable MRI timer ...
(Date:10/16/2014)... 16, 2014  One of California,s ... Office of the Patient Advocate — this week recognized ... in the state for the seventh consecutive year. ... Northern California and Kaiser Permanente Southern California are the ... to earn a four-star rating — the highest possible ...
Breaking Medicine Technology:Pharma Cool Chain & CRT Benchmarking Report 2Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 2Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 3Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 4Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 5Kaiser Permanente's California Health Plans Rated Highest for Quality for Seventh Consecutive Year 2Kaiser Permanente's California Health Plans Rated Highest for Quality for Seventh Consecutive Year 3
(Date:10/19/2014)... October 19, 2014 DENVER (October 20, ... and Washington State in the outright legalization of recreational ... advice for pro-cannabis activists in those states and elsewhere ... place, or prepare for chaos. , Fox is founder ... is one of Colorado’s first recreational dispensaries. , ...
(Date:10/19/2014)... 19, 2014 Theme and plugin developers from ... Final Cut Pro X entitled ProSketchy. , “ProSketchy allows ... any video project.” Said Christiana Austin, CEO of Pixel Film ... their own sketch style text.” , With ProSketchy users now ... text all with in Final Cut Pro X. Users have ...
(Date:10/18/2014)... The famous review site Top10BestSEOHosting.com has recently compared ... host suppliers carefully, today it announces that HostMonster, GreenGeeks ... the first half of 2014. , HostMonster is ... hosting package helps business companies and individuals get high-powered ... top rated hosting provider, it insists on offering outstanding ...
(Date:10/18/2014)... (PRWEB) October 19, 2014 Bon Secours ... in long-term and rehabilitation care in the Riverdale section ... Beato, chief executive officer, was honored by New Jersey ... CHA Corporate Alumni award at their 30th Annual Gala ... in healthcare administration from New Jersey City University in ...
(Date:10/18/2014)... October 19, 2014 Stafford Communications ... part in the breast cancer awareness program called “Sleep ... movement of pink pajama parties where women and men ... , In support of the program, Stafford’s employees wore ... the Estroven Facebook Page. In exchange, Stafford Communications and ...
Breaking Medicine News(10 mins):Health News:Cannabis CEO Warns Those States Considering a Legal Marijuana Market to Do Their Homework First 2Health News:Cannabis CEO Warns Those States Considering a Legal Marijuana Market to Do Their Homework First 3Health News:Announcing a New Plugin for Final Cut Pro X ProSketchy from Pixel Film Studios 2Health News:Announcing a New Plugin for Final Cut Pro X ProSketchy from Pixel Film Studios 3Health News:Top10BestSEOHosting.com: HostMonster, GreenGeeks And FatCow Are The Best PHP Hosting Suppliers In The First Half Of 2014 2Health News:Carlos G. Beato Honored by New Jersey City University’s Council on Hispanic Affairs (CHA) 2Health News:Carlos G. Beato Honored by New Jersey City University’s Council on Hispanic Affairs (CHA) 3Health News:Stafford Communications Holds Second Annual Celebration to Raise Money for Breast Cancer 2Health News:Stafford Communications Holds Second Annual Celebration to Raise Money for Breast Cancer 3
... News) -- Media multitasking -- the use of more than ... -- may have some positive effects, a new study suggests. ... which is especially common in young people and could include ... or social networking -- have received widespread publicity. But ...
... CINCINNATINew research at the University of Cincinnati (UC) ... a complex process that can provide cells with ... circumstances autophagy can protect tumor cells from chemotherapy, ... time in a hidden, dormant, metastatic state. ...
... , SUNDAY, April 15 (HealthDay News) -- A ... regions linked to fractures and osteoporosis. Variations in ... bone-weakening disease, the investigators reported in a new study published ... . The study authors added that their findings could ...
... appear to be rising, especially among high school students, ... is alarming and indicates more coaches and athletic trainers ... the game, according to researchers based at the University ... the number of football-related brain injuries with permanent disability ...
... Cancer is much more likely in the elderly than the ... disease and the often-toxic side effects of treatment. But ... The University of Texas Health Science Center at San Antonio shows ... younger patients can be used to help the elderly, with less ...
... , FRIDAY, April 13 (HealthDay News) -- In a new study ... of sun damage, middle schoolers showed evidence of levels of UV ... Not only can the technology spot who is most vulnerable ... noted, but it could also be used as a powerful deterrent ...
Cached Medicine News:Health News:Media Multitasking Might Have Mental Upside 2Health News:Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer 2Health News:Certain Genetic Regions May Be Tied to Osteoporosis 2Health News:Football-related catastrophic brain injuries on the rise 2Health News:Football-related catastrophic brain injuries on the rise 3Health News:Immunotherapy for elderly cancer patients finds new promise in drug combination 2Health News:Immunotherapy for elderly cancer patients finds new promise in drug combination 3Health News:Even Young Teens Show Signs of Sun Damage 2Health News:Even Young Teens Show Signs of Sun Damage 3Health News:Even Young Teens Show Signs of Sun Damage 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: